ABOS
Acumen Pharmaceuticals Inc.
Company Overview
| Mkt Cap | $115.70M | Price | $1.57 |
| Volume | 82.62K | Change | +0.64% |
| P/E Ratio | -1.1 | Open | $1.55 |
| Revenue | -- | Prev Close | $1.56 |
| Net Income | $-102.3M | 52W Range | $0.86 - $2.47 |
| Div Yield | N/A | Target | $6.75 |
| Overall | 39 | Value | 60 |
| Quality | -- | Technical | 18 |
No chart data available
About Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize Sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Latest News
Acumen Pharmaceuticals Appoints New Board Chairman
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABOS | $1.57 | +0.6% | 82.62K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Acumen Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW